Literature DB >> 18693083

Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia.

Brian Dean1, Nicola Crossland, Simone Boer, Elizabeth Scarr.   

Abstract

We have shown a decrease in cortical serotonin(2A) receptors using tissue sections, but not with washed membranes, from the same cohort of subjects. These discrepant findings led us to determine if we could obtain similar results using samples from the same tissue block. Our studies used single-point saturation analyses to estimate the total number of [(3)H]ketanserin binding sites in tissue sections, crude homogenate, membrane-enriched and cytosol-enriched tissue samples from Brodmann's area 9. There were significant decreases in the levels of [(3)H]ketanserin binding using tissue sections (mean+/-SD: 38+/-16 vs. 56+/-16 fmol/mg ETE; p=0.008) and crude tissue homogenates (131+/-53 vs. 168+/-38 fmol/mg protein; p<0.05) from subjects with schizophrenia compared to that in controls. By contrast, there was no significant difference in radioligand binding to the membrane-enriched (155+/-95 vs. 145+/-48 fmol/mg protein; p=0.72) or cytosol-enriched (8.6+/-14 vs. 7.5+/-10 mol/mg protein; p=0.85) tissue fraction. Significantly, adding 10(-5) M risperidone or chlorpromazine, as surrogates for residual antipsychotic drugs in the CNS, to crude homogenate from control subjects did not alter [(3)H]ketanserin binding. Our data therefore is consistent with the hypothesis that apparent decreases in serotonin(2A) receptors in schizophrenia are due to altered levels of a regulatory factor(s) that modulates the binding of ligands to the serotonin(2A) receptor and that separating the membrane and cytosol removes this regulatory control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18693083     DOI: 10.1016/j.schres.2008.06.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

Authors:  Hans Rasmussen; Bjorn H Ebdrup; David Erritzoe; Bodil Aggernaes; Bob Oranje; Jan Kalbitzer; Lars H Pinborg; William F C Baaré; Claus Svarer; Henrik Lublin; Gitte M Knudsen; Birte Glenthoj
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

Review 2.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

3.  Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects.

Authors:  Carolina Muguruza; José L Moreno; Adrienne Umali; Luis F Callado; J Javier Meana; Javier González-Maeso
Journal:  Eur Neuropsychopharmacol       Date:  2012-11-21       Impact factor: 4.600

4.  Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia.

Authors:  Shaun Hopper; Geoffrey Mark Pavey; Andrea Gogos; Brian Dean
Journal:  Int J Neuropsychopharmacol       Date:  2019-10-01       Impact factor: 5.176

5.  Opposite alterations of 5-HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile.

Authors:  Rebeca Diez-Alarcia; Carolina Muguruza; Guadalupe Rivero; Aintzane García-Bea; Vanessa Gómez-Vallejo; Luis F Callado; Jordi Llop; Abraham Martín; J Javier Meana
Journal:  Transl Psychiatry       Date:  2021-05-20       Impact factor: 6.222

6.  Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia.

Authors:  Marta Krzyżanowska; Johann Steiner; Ralf Brisch; Christian Mawrin; Stefan Busse; Katharina Braun; Zbigniew Jankowski; Hans-Gert Bernstein; Bernhard Bogerts; Tomasz Gos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-05       Impact factor: 5.270

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.